Biotech News
Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications
Approval introduces an extended dosing regimen of Libtayo 700 mg given every six weeks, following initial 12 weeks of treatment with Libtayo 350 mg every three weeks Also approved is an option of reducing subsequent infusion times of Libtayo 350 mg by up to half, from 30 minutes to 15 minutes,
